Read More

Sosei Heptares and AbbVie Announced New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases; Sosei Heptares Eligible to Receive up to $80M in Upfront, Near-term Milestone Payments; Up to $1….

Sosei Group Corporation ("the Company"; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR)

ABBV